Cumulative incidence of ICH in patients with glioma. (A) The 1-year incidence of any ICH was 28.1% in the enoxaparin cohort and 13.5% in the control cohort after glioma diagnosis (Gray test P = .37); (B) measurable ICH was 18.8% compared with 7.8%, respectively, (Gray test P = .05); and (C) major ICH was 14.7% vs 2.5%, respectively (Gray test P = .036). The enoxaparin cohort is shown in red, and the control cohort is shown in blue.